Cymed MicroSkin manufactures and distributes ostomy pouching systems featuring MicroSkin adhesives, which are transparent, hypoallergenic polyurethane films designed for comfort and security in ostomy care.

Cymed MicroSkin

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Coloplast A/S

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

ConvaTec Group Plc

Hollister Incorporated develops, manufactures, and markets healthcare products for ostomy care, continence care, and critical care.

Metric
Company Name	Cymed MicroSkin	Coloplast A/S	ConvaTec Group Plc	Hollister
Symbol		COLO-B	CTEC
MSH ID	COM:CYMEDOSTOMY	COM:COLOPLAST	COM:CONVATECGROUP	COM:HOLLISTER
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Medical Devices	Medical - Instruments & Supplies	Medical - Instruments & Supplies	Medical Devices and Supplies
Country	US	DK	GB	US
Stage
Employee Count		15.93K	10.14K
Website	cymedostomy.com	coloplast.com	convatecgroup.com	hollister.com
LinkedIn		coloplast	convatec
Founders

Metric
Market Cap	27.06B	63.14M
Enterprise Value
Monthly Web Traffic	87.07K
Web Traffic Growth	-0.17
Valuation
Raised Capital

Metric
Revenue	3.83B	2.14B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.48B	1.20B
EBITDA	1.21B	482.20M
Operating Income	1.05B	262.70M
Net Income	715.45M	130.30M
EPS	3.18	0.06
Diluted EPS	3.18	0.06
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68	0.56
Operating Profit Margin	0.27	0.14
EBITDA Margin	0.32	0.23
Net Profit Margin	0.19	0.07
Return on Equity	0.42	0.09
Return on Assets	0.10	0.04
Return on Capital Employed	0.23	0.09

COM:CYMEDOSTOMY

Cymed MicroSkin

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	35.22	189.47
P/B Ratio	9.74	3.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	8.41	3.56
EV Multiple	23.81	13.58

Metric
Days Sales Outstanding
Days Payables Outstanding	57.80	257.98
Days Inventory Outstanding	157.08	159.32
Operating Cycle	236.45	230.09
Cash Conversion Cycle	185.86	146.81
Asset Turnover	0.54	0.61

Metric
Operating Cash Flow	391.71M	367.40M
Free Cash Flow	226.59M	238.20M
Cash Flow to Debt	0.26	0.28
Operating Cash Flow/Sales	0.22	0.17
Free Cash Flow Yield	0.02	0.01

Metric
Cash & Equivalents	111.59M	97.60M
Accounts Receivable	-71.66M
Inventory	520.02M	396.10M
Goodwill	2.74B	1.30B
Debt to Capitalization	0.59	0.46
Debt to Assets	0.41	0.39
Current Ratio	0.61	1.70
Quick Ratio	0.56	1.27

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue	0.04	0.04
SG&A to Revenue	0.05	0.38